<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">1764386</article-id><article-id pub-id-type="pmc">1977835</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rubens</surname><given-names>R. D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaye</surname><given-names>S. B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Soukop</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>C. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brampton</surname><given-names>M. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>A. L.</given-names></name></contrib></contrib-group><aff>ICRF Department of Clinical Oncology, UMDS, Guy's Hospital, London.</aff><pub-date pub-type="ppub"><month>12</month><year>1991</year></pub-date><volume>64</volume><issue>6</issue><fpage>1187</fpage><lpage>1188</lpage><abstract><p>Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00076-0213.tif" xlink:title="scanned-page" xlink:role="1187" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00076-0214.tif" xlink:title="scanned-page" xlink:role="1188" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

